Phosphodiesterase 5 Inhibitors
"Phosphodiesterase 5 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
| Descriptor ID |
D058986
|
| MeSH Number(s) |
D27.505.519.389.735.500
|
| Concept/Terms |
Phosphodiesterase 5 Inhibitors- Phosphodiesterase 5 Inhibitors
- Inhibitors, Phosphodiesterase 5
- Phosphodiesterase Type 5 Inhibitors
- PDE-5 Inhibitors
- Inhibitors, PDE-5
- PDE 5 Inhibitors
- PDE5 Inhibitors
- Inhibitors, PDE5
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 5 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 5 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 5 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 5 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 11 | 11 | 22 |
| 2018 | 9 | 4 | 13 |
| 2019 | 7 | 1 | 8 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phosphodiesterase 5 Inhibitors" by people in Profiles.
-
Targeting the SARS-CoV-2 3CLpro and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors. Future Cardiol. 2021 08; 17(5):765-768.
-
The Role of Phosphodiesterase-5 Inhibitors in COVID-19: An Exploration of Literature From Similar Pathologies. J Intensive Care Med. 2021 Jan; 36(1):3-8.
-
Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection? Sex Med Rev. 2021 01; 9(1):15-22.
-
[Recommendations of the Committee of Andrology and Sexual Medicine of the AFU concerning the management of andrological and sexual medicine pathologies during the COVID-19 crisis]. Prog Urol. 2021 Jun-Jul; 31(8-9):495-502.
-
The war against the SARS-CoV2 infection: Is it better to fight or mitigate it? Med Hypotheses. 2020 Oct; 143:110129.
-
Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology. 2021 01; 9(1):33-38.
-
COVID-19 in a Patient with ß-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Hemoglobin. 2020 May; 44(3):218-220.
-
Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology. Clin Immunol. 2020 05; 214:108414.
-
Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. Eur Respir J. 2019 10; 54(4).
-
PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. J Clin Endocrinol Metab. 2019 07 01; 104(7):2623-2636.